Core Insights - Puma Biotech reported quarterly earnings of $0.10 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, and showing a significant improvement from a loss of $0.05 per share a year ago, resulting in an earnings surprise of 400% [1] - The company achieved revenues of $46 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.65% and increasing from $43.8 million year-over-year [2] Earnings Performance - Over the last four quarters, Puma Biotech has consistently surpassed consensus EPS estimates, achieving this four times [2] - The company had an earnings surprise of 207.14% in the previous quarter, where it reported earnings of $0.43 per share against an expectation of $0.14 per share [1] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.12 on revenues of $49.38 million, and for the current fiscal year, it is $0.54 on revenues of $216.4 million [7] - The estimate revisions trend for Puma Biotech is currently favorable, leading to a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Puma Biotech belongs, is currently ranked in the top 33% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Skillz Inc. (SKLZ) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $1.09. This compares to loss of $1.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15.60%. A quarter ago, it was expected that this company would post a loss of $1.07 per share when it actually produced a loss of $1.50, delivering a surprise of -40.19%.Over the last four quarters, the company has surpassed c ...

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.95 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -44.44%. A quarter ago, it was expected that this company would post a loss of $0.86 per share when it actually produced a loss of $0.89, delivering a surprise of -3.49%.Over the last four quarters, the company has s ...

Company Performance - Zymeworks Inc. reported a quarterly loss of $0.30 per share, better than the Zacks Consensus Estimate of a loss of $0.45, and an improvement from a loss of $0.42 per share a year ago, resulting in an earnings surprise of 33.33% [1] - The company posted revenues of $27.11 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 57.36%, compared to revenues of $10.03 million in the same quarter last year [2] - Over the last four quarters, Zymeworks has surpassed consensus EPS estimates four times, but has only topped consensus revenue estimates once [2] Stock Outlook - Zymeworks shares have declined approximately 22.5% since the beginning of the year, while the S&P 500 has decreased by 4.3% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.51 for the coming quarter and -$1.75 for the current fiscal year [4][7] Industry Context - The Medical - Biomedical and Genetics industry, to which Zymeworks belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Zymeworks' stock performance [5]

分组1 - Willdan Group reported quarterly earnings of $0.63 per share, exceeding the Zacks Consensus Estimate of $0.44 per share, and up from $0.40 per share a year ago, representing an earnings surprise of 43.18% [1] - The company posted revenues of $85.34 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 15.24%, although this is a decrease from year-ago revenues of $122.49 million [2] - Willdan has outperformed the S&P 500, with shares increasing about 5.3% since the beginning of the year, while the S&P 500 has declined by -4.3% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.71 on revenues of $81.4 million, and for the current fiscal year, it is $2.75 on revenues of $323.7 million [7] - The Zacks Industry Rank places the Business - Services sector in the top 21% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Financial Performance - Cantaloupe reported quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.10 per share, but showing an increase from $0.06 per share a year ago, representing an earnings surprise of -20% [1] - The company posted revenues of $75.43 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 4.31%, compared to year-ago revenues of $67.9 million [2] - Over the last four quarters, Cantaloupe has surpassed consensus EPS estimates just once and topped consensus revenue estimates only once [2] Stock Performance - Cantaloupe shares have declined approximately 13.6% since the beginning of the year, while the S&P 500 has decreased by -4.3% [3] - The current Zacks Rank for Cantaloupe is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is $0.11 on revenues of $84.48 million, and for the current fiscal year, it is $0.32 on revenues of $307.86 million [7] - The outlook for the Financial Transaction Services industry, where Cantaloupe operates, is currently in the top 36% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

PDF Solutions (PDFS) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.15 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.53%. A quarter ago, it was expected that this provider of software and services for semiconductor makers would post earnings of $0.24 per share when it actually produced earnings of $0.25, delivering a surprise of ...

Company Performance - Sight Sciences, Inc. reported a quarterly loss of $0.28 per share, which was better than the Zacks Consensus Estimate of a loss of $0.29, and an improvement from a loss of $0.33 per share a year ago, indicating an earnings surprise of 3.45% [1] - The company posted revenues of $17.51 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.95%, although this represents a decline from year-ago revenues of $19.27 million [2] - Over the last four quarters, Sight Sciences has exceeded consensus EPS estimates three times and has topped consensus revenue estimates three times as well [2] Stock Performance - Sight Sciences shares have declined approximately 21.4% since the beginning of the year, contrasting with the S&P 500's decline of 4.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.30 on revenues of $18.38 million, and for the current fiscal year, it is -$1.15 on revenues of $72.02 million [7] Industry Outlook - The Medical - Instruments industry, to which Sight Sciences belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Group 1: Earnings Performance - Diodes reported quarterly earnings of $0.19 per share, exceeding the Zacks Consensus Estimate of $0.18 per share, but down from $0.28 per share a year ago, representing an earnings surprise of 5.56% [1] - The company posted revenues of $332.11 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.47%, compared to year-ago revenues of $301.97 million [2] - Over the last four quarters, Diodes has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Group 2: Stock Performance and Outlook - Diodes shares have declined approximately 36.4% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.41 on revenues of $354.9 million, and for the current fiscal year, it is $1.82 on revenues of $1.43 billion [7] Group 3: Industry Context - The Electronics - Semiconductors industry, to which Diodes belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The current estimate revisions trend for Diodes is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]

Serve Robotics Inc. (SERV) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.37 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 23.81%. A quarter ago, it was expected that this company would post a loss of $0.19 per share when it actually produced a loss of $0.23, delivering a surprise of -21.05%.Over the last four quarters, the company has sur ...